Navigation Links
Alfacell Updates Status of ONCONASE(R) Phase III Clinical Program
Date:1/30/2008

SOMERSET, N.J., Jan. 30 /PRNewswire-FirstCall/ -- Alfacell Corporation (Nasdaq: ACEL) today announced that 311 evaluable events (patient deaths) have occurred in the Phase IIIb clinical trial of its lead compound, ONCONASE, for the treatment of patients with unresectable malignant mesothelioma. Enrollment in the ONCONASE Phase IIIb clinical trial was closed on Sept. 30, 2007. A total of 428 patients were enrolled in the trial.

In accordance with the statistical plan for the study, the company must wait until 316 evaluable events have occurred to conduct the formal statistical analysis required to complete the final sections of the ONCONASE rolling New Drug Application (NDA). To be considered evaluable, patients must meet all of the eligibility requirements for the study and receive at least one dose of study drug.

About ONCONASE(R)

ONCONASE is a first-in-class product candidate based on Alfacell's proprietary ribonuclease (RNase) technology. A natural protein isolated from the leopard frog, ONCONASE has been shown in the laboratory and clinic to target cancer cells while sparing normal cells. ONCONASE triggers apoptosis, the natural death of cells, via multiple molecular mechanisms of action.

About Alfacell Corporation

Alfacell Corporation is the first company to advance a biopharmaceutical product candidate that works in a manner similar to RNA interference (RNAi) through late-stage clinical trials. The product candidate, ONCONASE, is an RNase that overcomes the challenges of targeting RNA for therapeutic purposes while enabling the development of a new class of targeted therapies for cancer and other life-threatening diseases. In addition to an ongoing Phase IIIb study in malignant mesothelioma, Alface
'/>"/>

SOURCE Alfacell Corporation
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. Paper in International Journal of Oncology Reports Alfacells ONCONASE(R) Suppresses Intracellular Oxidative Stress
2. Alfacell Updates Status of ONCONASE(R) Phase III Clinical Program
3. Alfacell Corporation to Present at UBS Global Life Sciences Conference
4. Alfacell Reports Financial Results for First Quarter of Fiscal 2008
5. WallSt.net (www.wallst.net) Updates the Investment Community Through an All-New Interview With RegeneRx Biopharmaceuticals CEO
6. Diamyd Updates Gene Therapy Program and Outlines Plans for Phase I Clinical Trial for Treatment of Cancer Pain
7. Wyeth Presents New Phase 3 Data and Updates Regulatory Timing for NDA Filing of Bazedoxifene/Conjugated Estrogens
8. Alliance Pharmaceutical Corp. Updates Oxygent(TM) Clinical Development Plan
9. Imaging Diagnostic Systems Updates PMA Filing Status for the New CT Laser Breast Imaging System
10. BioCryst Updates Peramivir Clinical Development Plan
11. US FDA Grants Orphan Drug Status to Immtechs Pafuramidine for Treatment of African Sleeping Sickness
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/20/2008)...irstCall/ -- Duska Therapeutics,Inc., (OTC Bulle...itted its,pivotal Phase 3 ATPace clinical trial p...sment (SPA) procedure with the U.S. Food and Drug ...g an agreement with the FDA, Duska intends to init...-controlled and randomized Phase 3,clinical trial...
(Date:11/20/2008)...wire/ -- The Scandinavian-based drug,development ...tudies on its,lead antimicrobial candidate LTX-10...ies showed that the novel lytic peptidomimetic has...ly better towards killing Staphylococcus,aureus a...ard drugs. In,addition to this it has proven effe...
(Date:11/19/2008)...gs on critical enzyme,s regulation may hold key to...orders , , MEMPHIS, Tenn., Nov. 19 /PRNewsw...n,s Research Hospital have gained new insights int...s called calpains. , , As the cell,s molec...ular processes, including the movement of cells in...
(Date:11/18/2008)...ll/ -- NeuroDiscovery Ltd (ASX:,NDL), a specialty...t Company,and Sosei Group Corporation ("Sosei"; ... biopharmaceutical company, today announce that Ne...inical efficacy data for NSL-043/SD118.,This inve...athic pain and has,successfully completed Phase I...
Breaking Medicine Technology:Duska Therapeutics Applies for Phase 3 Special Protocol Assessment 2Duska Therapeutics Applies for Phase 3 Special Protocol Assessment 3Duska Therapeutics Applies for Phase 3 Special Protocol Assessment 4Lytix Presents LTX-109 Anti-Microbial Data at ICAAC 2New Insight Into the Controls on a Go-To Enzyme 2New Insight Into the Controls on a Go-To Enzyme 3Sosei and NeuroSolutions Present Further Data on NSL-043/SD118 at the Society for Neuroscience 38th Annual Meeting 2Sosei and NeuroSolutions Present Further Data on NSL-043/SD118 at the Society for Neuroscience 38th Annual Meeting 3Industrial Control Repair Named Honda of America Manufacturings 2007 Supplier of the Year 21364 1Industrial Control Repair Named Honda of America Manufacturings 2007 Supplier of the Year 21364 2Low Vitamin D Levels May Boost Mens Heart Attack Risk 21362 1Phase 3 results for alogliptin 21359 1Phase 3 results for alogliptin 21359 2Phase 3 results for alogliptin 21359 3Public Invited to Learn to Work Safe Live Well During Safety Day n June 11 21356 1
...d Stability,Significantly Longer than Placebo and ...e with Placebo , MARIETTA, Ga. and COLLEGEVILLE, P...yeth Pharmaceuticals, a division of Wyeth,(NYSE:WY...lts on,bifeprunox, an investigational treatment fo...ay at the 2007 annual meeting of,the American Psyc...
...e as Future-Generation,Technology, BARCELONA, Spai...oday announced positive results from ABSORB, the w...and performance of a fully,bioabsorbable drug elut...rtery disease. Nine-month results from the first 3...roPCR meeting,demonstrated no stent thrombosis an...
Other Medicine Technology:New Long-Term Data Analyses for Bifeprunox Show Favorable Effects,Versus Placebo in Stabilized Patients with Schizophrenia 2New Long-Term Data Analyses for Bifeprunox Show Favorable Effects,Versus Placebo in Stabilized Patients with Schizophrenia 3New Long-Term Data Analyses for Bifeprunox Show Favorable Effects,Versus Placebo in Stabilized Patients with Schizophrenia 4New Long-Term Data Analyses for Bifeprunox Show Favorable Effects,Versus Placebo in Stabilized Patients with Schizophrenia 5Abbott Announces Positive Nine-Month Results From the World's First,Clinical Trial of a Fully Bioabsorbable Drug Eluting Coronary Stent 2Abbott Announces Positive Nine-Month Results From the World's First,Clinical Trial of a Fully Bioabsorbable Drug Eluting Coronary Stent 3
(Date:11/21/2008)...swire/ -- The University of Texas M. D. Anderson...tive effort to eradicate breast cancer in Panama t... and Research of the Americas today at an event wi..., and Vivian Fernandez de Torrijos, the First Lady...he initiative are the U.S. Department of State and...
(Date:11/21/2008)... -- NursingCenter.com, the premier site,for onlin...ontent, has been,updated to improve the interacti...owered by Lippincott Williams & Wilkins (LWW),...iewed continuing education activities and free,ac...nursing journals.,Lippincott Williams & Wilki...
(Date:11/21/2008)...e-USNewswire/ -- U.S. News & World Report and ...) ranked BlueChoice(R) HealthPlan of South Carolin...TM), published in U.S. News & World Report,s i...nking ranks the nation,s best health plans based o...ccreditation scores. NCQA and U.S. News & Worl...
(Date:11/21/2008)...ewswire-FirstCall/ -- Today, prescription drugs ar...ating 88 percent of patients suffering chronic con...a chronic condition account for 96 percent of all ...edical costs. A proprietary new pharmacy model de..., Inc. (NYSE: MHS ) significantly reduces critic...
Breaking Medicine News(10 mins):Health News:First Lady Laura Bush's Partnership for Breast Cancer Awareness and Research Extends to Panama 2Health News:First Lady Laura Bush's Partnership for Breast Cancer Awareness and Research Extends to Panama 3Health News:NursingCenter.com Launches New Features to Improve User Experience 2Health News:NursingCenter.com Launches New Features to Improve User Experience 3Health News:BlueChoice HealthPlan Ranks in Top Third of America's Best Health Plans 2Health News:New Data: Advanced Pharmacy Model Significantly Reduces Gaps in Care for Patients with Chronic and Complex Conditions; Improves Clinical and Financial Outcomes 2Health News:New Data: Advanced Pharmacy Model Significantly Reduces Gaps in Care for Patients with Chronic and Complex Conditions; Improves Clinical and Financial Outcomes 3Health News:New Data: Advanced Pharmacy Model Significantly Reduces Gaps in Care for Patients with Chronic and Complex Conditions; Improves Clinical and Financial Outcomes 4Health News:New Data: Advanced Pharmacy Model Significantly Reduces Gaps in Care for Patients with Chronic and Complex Conditions; Improves Clinical and Financial Outcomes 5Health News:New Data: Advanced Pharmacy Model Significantly Reduces Gaps in Care for Patients with Chronic and Complex Conditions; Improves Clinical and Financial Outcomes 6
...in long-term weight reduction and post potential h...e than a short time, accordinhg to an advisory fro...ittee in Circulation published in: Journal of the ...e diets increase fat intake and reduce nutritional...
...sorder (ADHD) who use stimulants like Ritalin are ...he study in rats suggests that stimulant treatment... cocaine in adulthood. // Many children and teens...medication, the best-known being Ritalin. These dr...
...y not only an effective treatment for malaria, the...ears to be similar to the mechanism they use to f...f Toronto report these findings at the 50th Annual...opical Medicine and Hygiene in Atlanta.// The comp...
...ell damage from long-term use of the party drug ec...ey stop taking the drug. Studies have shown that t...as MDMA, can damage nerve endings that release ser...mory, sleep and sex. The drug also appears to dama...
Other Medicine News:Health News:High-protein diets may pose health risks 2
...e laboratory and a worldwide leader in innovative ...n extensive test menu of highly complex and unique... Owned by the University of Utah, ARUP Laboratorie...university teaching hospitals and children's hospi...
...e laboratory and a worldwide leader in innovative ...n extensive test menu of highly complex and unique... Owned by the University of Utah, ARUP Laboratorie...university teaching hospitals and children's hospi...
...sed in the ARED study, as well as the Lutein Antio... AMD disease progression in the study participants...ns efficacious amounts of nutrients suggested in p...as well as to support production of cellular (ATP)...
...ne and only vitamin and mineral formula proven eff... eye study (AREDS) 10-year trial. 4 tablets per da...sease Study (AREDS) by the National Eye Institute ...showed that a unique vitamin and mineral supplemen...
Medicine Products: